Ftse Mib
34.127,62
0,00%
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
NASDAQ
19.621,68
1,77%
Bitcoin
99.305,77
1,02%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Exelixis Inc (EXEL) Exelixis Inc (EXEL) Notizie

EXEL

Exelixis (EXEL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EXEL
DataOraFonteTitoloSimboloCompagnia
24/12/202402:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
29/11/202419:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
27/11/202422:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in DecemberNASDAQ:EXELExelixis Inc
26/11/202422:05Business WireExelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine TumorsNASDAQ:EXELExelixis Inc
07/11/202422:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in NovemberNASDAQ:EXELExelixis Inc
29/10/202421:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EXELExelixis Inc
29/10/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EXELExelixis Inc
29/10/202421:05Business WireExelixis Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
15/10/202422:05Business WireExelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024NASDAQ:EXELExelixis Inc
15/10/202419:57Business WireExelixis Announces Update on Second Patent Litigation Trial with MSN LaboratoriesNASDAQ:EXELExelixis Inc
14/10/202414:00Business WireExelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell CarcinomaNASDAQ:EXELExelixis Inc
09/10/202414:30PR Newswire (Canada)ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORSNASDAQ:EXELExelixis Inc
16/09/202414:45Business WireExelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of MedicineNASDAQ:EXELExelixis Inc
15/09/202414:45Business WireExelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024NASDAQ:EXELExelixis Inc
28/08/202422:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in SeptemberNASDAQ:EXELExelixis Inc
06/08/202423:03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EXELExelixis Inc
06/08/202422:05Business WireExelixis Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
06/08/202414:30Business WireExelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine TumorsNASDAQ:EXELExelixis Inc
23/07/202422:05Business WireExelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024NASDAQ:EXELExelixis Inc
28/05/202422:05Business WireExelixis to Present at the William Blair 44th Annual Growth Stock ConferenceNASDAQ:EXELExelixis Inc
20/05/202414:00Business WireExelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USANASDAQ:EXELExelixis Inc
08/05/202422:11Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EXELExelixis Inc
07/05/202422:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in MayNASDAQ:EXELExelixis Inc
30/04/202422:05Business WireExelixis Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
16/04/202422:05Business WireExelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024NASDAQ:EXELExelixis Inc
27/02/202422:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in MarchNASDAQ:EXELExelixis Inc
13/02/202415:19Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EXELExelixis Inc
06/02/202422:49Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EXELExelixis Inc
06/02/202422:05Business WireExelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
01/02/202422:05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in FebruaryNASDAQ:EXELExelixis Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EXEL

La tua Cronologia

BIT
11COV
Bearer
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network